Amgen Aktie News

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.

Eli Lilly's stock trades at more than 30 times forward earnings, which is a steep price to pay right now. Amgen is a much cheaper option by comparison.

THOUSAND OAKS, Calif., Jan. 28, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2025 financial results on Tuesday, February 3, 2026, after the close of the U.S. financial markets.

Amgen Inc. is rated a Buy, driven by robust pipeline prospects and the transformative potential of its obesity drug candidate MariTide. Recent AMGN performance includes 12% revenue growth in Q3 2025, upwardly revised 2025 guidance, and healthy operating margins near 30%. Patent expiries will pressure legacy products, but new launches and biosimilars are expected to offset declines, with pipelin...

LAS VEGAS--(BUSINESS WIRE)--Sagebrush Health Services, a nonprofit organization serving over 10,000 Nevada patients, has filed a lawsuit against Amgen Inc. (NASDAQ: AMGN), alleging that Amgen acted unlawfully by unilaterally terminating the sale of discounted drugs to Sagebrush's clinics and improperly retracting millions of dollars in past discounts. These actions, Sagebrush maintains, tempora...

These drugmakers can perform well despite competition and patent cliffs facing them. Both have excellent dividend programs and have increased their payouts at a good clip.

Amgen reported early Phase 2 data suggesting patients kept weight off with less frequent dosing, a potential differentiator from Eli Lilly and Novo Nordisk.

U.S. telehealth firm Ro said on Tuesday it has entered a research collaboration with drugmaker Amgen to examine challenges patients and providers face in accessing obesity treatments, including GLP-1 therapies.